Should We Use N -Acetyltransferase Type 2 Genotyping To Personalize Isoniazid Doses?
- 1 May 2005
- journal article
- clinical trial
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 49 (5) , 1733-1738
Abstract
Isoniazid is metabolized by the genetically polymorphic arylamine N -acetyltransferase type 2 (NAT2). A greater number of high-activity alleles are related to increased acetylation capacity and in some reports to low efficacy and toxicity of isoniazid. The objective of this study was to assess individual isoniazid exposure based on NAT2 genotype to predict a personalized therapeutic dose. Isoniazid was administered to 18 healthy Caucasians (age 30 ± 6 years, body weight 74 ± 10 kg, five women) in random order as a 200-mg infusion, a 100-mg oral, and a 300-mg oral single dose. For the assessment of NAT2 genotype, common single nucleotide polymorphisms identifying 99.9% of variant alleles were characterized. Noncompartmental pharmacokinetics and compartmental population pharmacokinetics were estimated from isoniazid plasma concentrations until 24 h postdose by high-pressure liquid chromatography. The influence of NAT2 genotype, drug formulation, body weight, and sex on dose-normalized isoniazid pharmacokinetics was assessed by analysis of variance from noncompartmental data and confirmed by population pharmacokinetics. Eight high-activity NAT2*4 alleles were identified. Sex had no effect; the other factors explained 93% of the variability in apparent isoniazid clearance (analysis of variance). NAT2 genotype alone accounted for 88% of variability. Individual isoniazid clearance could be predicted as clearance (liters/hour) = 10 + 9 × (number of NAT2*4 alleles). To achieve similar isoniazid exposure, current standard doses presumably appropriate for patients with one high-activity NAT2 allele may be decreased or increased by approximately 50% for patients with no or two such alleles, respectively. Prospective clinical trials are required to assess the merits of this approach.Keywords
This publication has 27 references indexed in Scilit:
- The Influence of Human N-Acetyltransferase Genotype on the Early Bactericidal Activity of IsoniazidClinical Infectious Diseases, 2004
- Isoniazid Pharmacokinetics-Pharmacodynamics in an Aerosol Infection Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2004
- Polymorphism of the N -acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitisHepatology, 2002
- Population screening for isoniazid acetylator phenotypePharmacoepidemiology and Drug Safety, 2001
- N-Acetyltransferase2 Genotype Correlated with Isoniazid Acetylation in Japanese Tuberculous Patients.Biological and Pharmaceutical Bulletin, 2001
- Preliminary phenotypic map of chromosome 4p16 based on 4p deletionsAmerican Journal of Medical Genetics, 1995
- Genetically determined differences in drug metabolism as a risk factor in drug toxicityToxicology Letters, 1992
- N-acetyltransferasePharmacology & Therapeutics, 1989
- Genetically Determined Variability in Acetylation and Oxidation Therapeutic ImplicationsDrugs, 1985
- Genetic Control of Isoniazid Metabolism in ManBMJ, 1960